Home - Products - Others - Other Targets - 4-(4-Methoxyphenyl)-2-butanone

4-(4-Methoxyphenyl)-2-butanone

CAS No. 104-20-1

4-(4-Methoxyphenyl)-2-butanone( Anisylacetone )

Catalog No. M22648 CAS No. 104-20-1

4-(4-Methoxyphenyl)-2-butanone is an effective lure for the male melon fly.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    4-(4-Methoxyphenyl)-2-butanone
  • Note
    Research use only, not for human use.
  • Brief Description
    4-(4-Methoxyphenyl)-2-butanone is an effective lure for the male melon fly.
  • Description
    4-(4-Methoxyphenyl)-2-butanone is an effective lure for the male melon fly.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Anisylacetone
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    104-20-1
  • Formula Weight
    178.2
  • Molecular Formula
    C11H14O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc1ccc(CCC(C)=O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hymavathi A , Babu K S , Naidu V G M , et al. Bioactivity-guided isolation of cytotoxic constituents from stem-bark of Premna tomentosa[J]. Bioorganic & medicinal chemistry letters, 2009, 19(19):5727-5731.
molnova catalog
related products
  • 3,5-Dihydroxy-1-(3,4...

    (3R,5R)-3,5-dihydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane may have anti-adipogenic activity.

  • Hylambatin

    Hylambatin, a tachykinin, increases both plasma glucose and plasma insulin, whereas the secretion of glucagon was not affected. Hylambatin can be used in diabetes research.

  • Elezanumab

    Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.